Arcus Biosciences Advances Cancer Treatment with AB598 Study

Arcus Biosciences ((RCUS)) announced an update on their ongoing clinical study.

Arcus Biosciences is conducting a Phase 1/1b clinical study titled A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Therapy in Participants With Advanced Malignancies. The primary goal is to assess the safety and tolerability of AB598 in patients with advanced cancers, which is crucial for developing new cancer treatments.

The study tests AB598, administered as an intravenous infusion every three weeks, both as a monotherapy and in combination with other drugs like zimberelimab and FOLFOX. This combination aims to enhance treatment efficacy against advanced malignancies.

The study is interventional, non-randomized, and follows a sequential model without masking. Its primary purpose is treatment, focusing on evaluating the drug’s safety profile.

Key dates include the actual start date of October 13, 2023, with the last update submitted on July 30, 2025. These dates are important for tracking the study’s progress and potential market entry timelines.

This update could positively influence Arcus Biosciences’ stock performance by boosting investor confidence in its pipeline. The study’s progress may also impact competitors in the oncology sector as new treatments emerge.

The study is ongoing, and further details are available on the ClinicalTrials portal.